May 2023 Managing Neonatal Abstinence Syndrome: Screening and Medication Monitoring
Neonatal abstinence syndrome (NAS) affects infants who were exposed to opioids or other substances while in the womb.1 NAS has...
In Practice: Clinical Insights
Mar 2023 Novel Psychoactive Substances: Newly Identified Threats Detected in the Second Half of 2022
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit...
Feb 2023 Impacts of Bariatric Surgery
Bariatric Surgeries1,2,6 Restrictive procedures Sleeve gastrectomy Gastric banding Vertical banded gastroplasty Malabsorptive procedures – new pathways created Roux-en-Y gastric bypass...
Jan 2023 Novel Psychoactive Substances: What is Xylazine?
Substance use can take many forms and often involves many unknowns. One of the most important aspects of illicit substance...
Dec 2022 Medication Monitoring in a Changing Opioid Prescribing Landscape
The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice...
Nov 2022 Aegis’s Novel Psychoactive Substances Testing Menu Update
In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to...
